Arikayce Generic Name & Formulations
Mechanism of Action
Limitations of Use
Arikayce Dosage and Administration
Arikayce Boxed Warnings
Increased risk for respiratory adverse reactions potentially leading to hospitalizations. Discontinue if hypersensitivity pneumonitis, anaphylaxis or hypersensitivity reaction occurs; manage appropriately. Auditory/vestibular dysfunction; monitor closely; if ototoxicity occurs, manage and discontinue if appropriate. Risk for ototoxicity (known maternal history of ototoxicity due to aminoglycoside use or mitochondrial DNA variants); consider alternative therapies. Renal dysfunction or neuromuscular disorders (eg, myasthenia gravis); monitor closely. Elderly: monitor renal function. Embryo-fetal toxicity. Pregnancy: avoid use. Nursing mothers.
The bioavailability of Arikayce is expected to vary primarily from individual differences in nebulizer efficiency and airway pathology.
Serum protein bound: ≤10%.
Principally via glomerular filtration. Renal (7.42%). Half-life: ~5.9–19.5 hours.
Arikayce Adverse Reactions
Arikayce Clinical Trials
Arikayce Patient Counseling